Study finds exenatide, liraglutide are comparable

09/15/2011 | (free registration)

Data on more than 900 patients with type 2 diabetes showed those who took exenatide once-weekly for 26 weeks attained an average decrease of 1.28% in hemoglobin A1c levels, while those who took liraglutide once-daily for the same period had a 1.48% reduction in HbA1c rates. The exenatide group also had a mean weight loss of almost 6 pounds, while liraglutide-treated patients lost almost 8 pounds.

View Full Article in: (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
Minneapolis, MN
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Junior to Mid-Level FDA Associate
Morgan Lewis
Washington, DC
Senior Counsel – Regulatory Affairs
RAI Services Company
Winston-Salem, NC